The mechanism by which enoxaparin sodium–high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells

Linchao Sang1, Kangning Hao1, Luobin Ding1, Xiaoyu Shen1, Hui Sun2, Dehao Fu3 and Xiangbei Qi1*

Abstract
Objective: PMMA bone cement leads to the development of local thrombi. Our study found that ES-PMMA bone cement, a novel material, can reduce local thrombosis. We used a simple and reproducible animal model to confirm the reduction in local thrombosis and preliminarily explored the associated molecular mechanism.

Methods: New Zealand rabbits, which were used to model thrombosis using extracorporeal carotid artery shunts, were divided into the following three groups, with 10 rabbits in each group: the sham group, PMMA group and ES-PMMA group. Four hours after modelling, experimental samples were collected, and the degree of thrombosis was compared between the groups. The expression of thrombomodulin in endothelial cells was quantified in vascular tissues samples.

Results: Thrombosis was observed in the PMMA group and ES-PMMA group but not in the sham group. The thrombosis weight was 0.00732 ± 0.00089 g/cm in the PMMA group and 0.00554 ± 0.00077 g/cm in the ES-PMMA group (P < 0.001). Quantitative real-time polymerase chain reaction (RT–qPCR) and Western blotting revealed that the expression of CD40, which can regulate thrombosis in vascular endothelial cells, was significantly lower in the ES-PMMA group than in the PMMA group.

Conclusion: Compared with PMMA bone cement, ES-PMMA bone cement can reduce local thrombosis by decreasing the expression of the thrombus-associated regulatory protein CD40 in vascular endothelial cells.

Keywords: Thrombosis, Enoxaparin sodium, Bone cement, CD40, Endothelial cells

Background
Bone cement has been used for a long time in the clinic, and with the continuous development of joint replacement strategies, operation-related complications and adverse events have gradually emerged. The incidence of bone cement implantation syndrome (BCIS), one of the important and severe complications, is as high as 28% [1]. However, the exact mechanism of BCIS has not yet been fully determined. At present, it is believed that BCIS is mainly caused by allergic reactions, pulmonary embolism, complement activation and histamine release combined with an increase in pulmonary vascular resistance and ventilation/perfusion mismatch, eventually leading to acute hypoxia, right ventricular failure and cardiogenic shock [2]. Although pulmonary embolism is rare after joint replacement, the mortality rate is very high. According to relevant reports, the incidence of
pulmonary embolism after joint replacement may be as high as 0.2–0.4% [3].

The current research focus is the toxicity of bone cement particles in the blood, as thrombosis results from the activation of the human complement system and the human coagulation system due to thermal effects [4]. Thrombus shedding can lead to reductions in extremity venous thrombosis or pulmonary embolism, but whether the physical and chemical properties of bone cement can directly lead to local thrombosis has not been studied.

Enoxaparin sodium is an anticoagulant drug available as an injection or powder that is widely used for the prevention and treatment of thrombosis-related diseases in orthopaedic patients [5]. Enoxaparin sodium high-viscosity bone cement is a biomaterial made by mixing enoxaparin sodium powder with bone cement powder in a certain proportion and then mixing the product with liquid [6].

This study shows that high-viscosity bone cement can induce local thrombosis in animal models; confirms that compared with ordinary high-viscosity bone cement, enoxaparin sodium high-viscosity bone cement, a novel material, can reduce local thrombosis; and elucidates the preliminary molecular mechanism by which this material reduces local thrombosis, as described in detail below.

Material and method

Animal model, grouping and experimental reagents

Six-month-old male New Zealand rabbits (Wangdu Tongghui Animal Breeding Co., Ltd., animal certificate No.: 210426) (protocol approved by the Medical Ethics Committee of the Third Medical College of Hebei Medical University, ethics acceptance No. z2021–007-2) weighing 2.5 ± 0.5 kg were anaesthetized. An appropriate depth of anaesthesia was maintained with 20% urethane. The rabbits were placed in the supine position, and an extracorporeal carotid artery shunt was placed as described in the literature [7]. The rabbits were divided into three groups: the sham-operated group (FS group) (n = 10), ordinary high-viscosity polymethylmethacrylate (PMMA) bone cement group (Con group) (n = 10) and novel enoxaparin sodium high-viscosity polymethylmethacrylate (ES-PMMA) bone cement group (M group) (n = 10). To generate ES-PMMA, 8000 AXa IU enoxaparin sodium powder (Chengdu Baiyu, China) was premixed with 40g PMMA bone cement (Heraeus, Germany) [6] followed by liquid. Then, the mixture was placed under a high-power scanning electron microscope (SEM, Hebei Medical University Electron Microscopy Center, Hitachi, S-3500 N), and the characteristics of the two types of bone cement were compared. The bone cement was used to glue surgical silk thread in the different groups, and we ensured that the bone cement completely and evenly covered the thread. Then, the bone cement was inserted into the shunt and extended approximately 1 cm into the blood vessel through the shunt so that it made contact with the vascular endothelium. The bone cement was maintained in the circulation for 4 hours. Rabbits in the FS group underwent the same procedure as those in the other two groups except nothing was placed in the shunt. The procedures used for modelling and samples collected are shown in Fig. 1, and the characteristics of PMMA and ES-PMMA are shown in Fig. 2.
Sample collection
Four hours after modelling, we collected and analysed samples. Bone cement-induced thrombus samples were obtained from the Con group and M group, and the degree of thrombus attached to the thread covered with bone cement was determined. Vascular tissue sample that contacted the bone cement were stored in a −80 °C freezer and processed in the same manner as those from the FS group. The expression of thrombus-related regulatory proteins in endothelial cells in vascular tissue cells was determined by quantitative real-time polymerase chain reaction (RT–qPCR), Western blotting and immunofluorescence.

RT–qPCR analysis of the mRNA expression of thrombus-associated proteins in endothelial cells in vascular tissue
Total RNA was extracted from tissues from the different groups with TRIzol reagent (Invitrogen, USA) according to the manufacturer’s instructions. The mRNA was reverse transcribed with a PrimeScript RT Reagent Kit (Takara, Japan). A SYBR Premix Ex Taq Kit (Servicebio, Wuhan) was used for RT–qPCR on an iQ5 Real-Time PCR instrument (Applied Biosystems USA). The reaction conditions were as follows: 94 °C for 4 min, 94 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s for a total of 40 cycles. Each sample was analysed three times. The primer sequences for the polymerase chain reaction (PCR) were as follows: CD31: F, TCTTACGATGCC AGGTCTGA, and R, CATTTCGCGCATGGGAAATG GC; CD40: F, GCCGGGAACTAACAAGACAG, and R, GCCGGTAGCCTATCTATGG; CD62p: F, AGTGTC TAGCTGTCCAGTGC, and R, AGTCACCAAGG GATGCCAG; CD106: F, GCCCTTTGGAGGTTGAG AA, and R, GAACTTGTAGCCCTCGCTG; endothe- lin: F, TGGACGGCTACAATCC; thrombomodulin: F, TTC CTCTGCGAGTCCCCCTT, and R, CGTACAGGTTCA GCTCCAAG; and GAPDH: F, TGGAAATCCACTGGCG TCTTC, and R, TCATGAGCCCTCCACACATG. The 2⁻ΔΔCT method was used for quantitative analysis of relative mRNA expression, and a histogram was drawn. The expression of each gene was normalized to the expression of GAPDH.

Western blot analysis
Blood vessel samples from the different groups were washed with ice-cold PBS and then lysed with RIPA buffer (Beyotime, China) containing protease inhibitor. The protein samples were separated on SDS–PAGE gels of different percentages and then transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, USA). The membrane was incubated with primary antibodies against CD31 (Abcam, UK), CD40 (Abcam, UK), CD62P (Abcam, UK), CD106 (Abcam, UK), endothelin (Abcam, UK) and thrombomodulin (Abcam, UK) at 4 °C with shaking overnight and then with a corresponding secondary antibody for 1.5 hours. Western LightningTM Chemiluminescence Reagent was used to develop the blot for 30 s, and then the membrane was immediately placed in an exposure box and exposed for 1 min in a darkroom. The membrane was imaged and analysed with a LabWorksTM gel imaging and analysis system (UVP, USA). GAPDH was used as an internal control.

Tissue immunofluorescence
Frozen vascular tissues from the different groups were allowed to stand for 1 hour and then sliced at a thickness of 8 μm. The tissues were placed in Triton X-100 (mass fraction 0.5%) for 10 min, blocked with 4% goat serum albumin and incubated with an anti-cd40 primary antibody (Abcam, UK) diluted 1:200 overnight at 4 °C. Then,
the tissues rinsed with PBS 3 times, incubated with anti-sheep and anti-rabbit IgG secondary antibodies (Abcam, UK) diluted 1:400, rinsed with PBS at room temperature for 2 hours, dried, observed and photographed under a fluorescence microscope. Image-Pro Plus software was used for semiquantitative analysis of the images, and the fluorescence intensity was calculated.

Data analysis
All experiments were carried out three times. The results are expressed as the mean ± standard deviation. T test was used for comparisons between groups. Statistical analysis was performed using SPSS software (version 17.0). \(P \leq 0.05\) was considered statistically significant. Significant is indicated as follows: *, \(P \leq 0.05\); **, \(P \leq 0.01\); and ***, \(P \leq 0.001\).

Result
Characterization of PMMA and ES-PMMA by electron microscopy
Animals in the M group were treated with 8000 AXa IU enoxaparin sodium mixed with 40g PMMA powder. Under an electron microscope, it was observed that the gaps between the particles on the surface of ES-PMMA were filled with a syrup-like substance, which we considered the attached enoxaparin.

Analysis of thrombus in different samples
Four hours after the establishment of the animal model, the thrombosis weight was \(0.00732 \pm 0.00089 \text{g/cm} \) in the Con group and \(0.00554 \pm 0.00077 \text{g/cm} \) that in the M group (\(P<0.001\)). The difference in thrombosis weight between the groups was significant. No thrombosis was observed in the FS group in our study (Supplementary Table 1).

Differential expression of thrombus-associated proteins in endothelial cells in vascular tissue
Vascular endothelial cells from the Con group and M group, which contacted the bone cement, were collected for RT–qPCR, Western blotting and immunofluorescence. Vascular endothelial cells from the FS group were collected for the same analyses. Relevant studies have shown that thrombosis is related to inflammation, a hypercoagulable state, vascular endothelial cell injury or functional regulation. Proteins related to thrombosis, mainly are CD62p, CD40, CD31, endothelin, thrombomodulin and CD106, are expressed by endothelial cells.
We measured the mRNA expression levels of six thrombus-related proteins in the samples by RT–qPCR. The results are shown in Fig. 3. We found that the expression of CD62p and CD40 was significantly decreased in the M group compared with the Con group (\(P<0.01\)) and that the expression of CD40 was significantly decreased in the FS group compared with the Con group (\(P<0.001\)). There was no significant difference in other indexes between the Con groups and M group (\(P>0.05\)).

The expression of these six proteins was assessed by Western blotting. As shown in Fig. 4, the protein expression of CD31 was decreased in the M group compared with the Con group (\(P<0.05\)), and the protein expression of CD40 was significantly decreased in the M group compared with the Con group (\(P<0.01\)). There was no significant difference in other indexes between the two groups.

**Fluorescence staining of CD40 for identification of vascular endothelial cells**

Given that CD40 mRNA and protein expression was significantly lower in the M group than in the Con group, immunofluorescence staining of CD40 in the three groups was performed. The results are shown in Fig. 5; base magnification: 200×.

**Discussion**

The application of high-viscosity bone cement in clinical practice is accompanied by BCIS [2, 8], which has an incidence rate as high as 28%. One of the causes of BCIS is embolism caused by bone cement implantation, including pulmonary embolism and lower limb venous embolism [9]. However, whether the physical and chemical properties of bone cement itself can cause local thrombosis to induce lower limb venous thrombosis or pulmonary embolism has not been reported.

We simulated the local surgical environment and studied whether bone cement could cause the development of thrombosis around the bone cement through quantitative analysis. Since bone cement is dispersed in the bodies of animals after the establishment of animal models of hip and knee replacement and it is very difficult to collect tissue samples around bone cement, we simulated the bone cement microenvironment during surgery. During joint replacement, the arteriovenous and...
small blood vessels around the joint that is removed during the operation, the small blood vessels in the medullary cavity and the blood circulating in the blood vessels contact bone cement. The main reasons for thrombosis include a slow endovascular blood stream, high blood condensation, platelet activation, endothelial cell injury or abnormal expression of thrombosis-related regulatory proteins. Due to its high viscosity, bone cement can affect the blood vessels and the composition of the blood flowing through them. We established a New Zealand rabbit model of extracorporeal carotid artery shunt and then implanted a silk thread covered in bone cement to simulate the microenvironment in which blood flows through the surface of bone cement so that it can contact the inner wall of blood vessels to assess its influence on tiny blood vessels. By using this model, we were able to quantitatively evaluate whether the physical and chemical properties of high-viscosity bone cement can cause the development of local thrombosis.

Our group has developed a novel material by mixing PMMA with ES and determined that the best ratio [6] was 8000 AXa IU ES:40 g PMMA. This bone cement can release heparin sodium to prevent coagulation when the required biomechanical strength is reached.

The reduction in the amount of heparin sodium released from bone cement can theoretically reduce the formation of local thrombosis without causing massive bleeding. We verified whether it can reduce the formation of local thrombosis. In the animal model, we found that thrombosis was attached to three threads covered with high-viscosity bone in the Con group. We also measured the thrombus weight, which was $0.00732 \pm 0.00089 \text{ g/cm}$. The thrombus weight in the experimental group was $0.00554 \pm 0.00077 \text{ g/cm}$. Although the experimental group exhibited thrombosis, there were significantly fewer thrombi in the presence of ES-PMMA than in the presence of ordinary high-viscosity bone cement.

Thrombosis is mainly caused by blood hypercoagulability, platelet activation, injury of vascular endothelial cells or abnormal expression of clot-related proteins [10–14]. Bone cement causes local thrombosis by directly contacting blood components or acting on vascular endothelial tissue. In this study, vascular tissues in contact with bone cement were selected to compare the influence of ES-PMMA and PMMA on the expression of thrombosis-related proteins in vascular endothelial cells and to illustrate the difference in the influence of these two types of bone cement on thrombosis by measuring the expression of these proteins. Among the many proteins expressed by endothelial cells, endothelin [15], vascular endothelial cell adhesion molecule [16], CD62p [17, 18], CD31 [19], thermoregulatory protein [20, 21], and CD40 [22, 23] are closely related to thrombosis. We assessed the differential expression of thrombus-related proteins in endothelial
cells by RT–qPCR and Western blotting and found that the expression of CD40 in the M group was significantly lower than that in the Con group. Immunofluorescence revealed that the fluorescence intensity of CD40 in the M group was lower than that in the Con group. In addition, relevant studies have proven that CD40 in endothelial cells has a regulatory effect on thrombosis [24]. CD40 is a member of the tumour necrosis factor receptor superfamily. The effect of enoxaparin sodium is mainly dependent on by anticoagulant factor Xa [25], which is a serine protease [26]. Serine protease exists in the digestive enzyme and complement system [27, 28]. The complement system is composed of inherent complement components, complement regulatory proteins and complement receptors [29]. Some complement components are expressed in vascular endothelial cells [30], while CD40 is expressed in B cells, mononuclear macrophages, dendritic cells and vascular endothelial cells [31]. Therefore, we found that compared with PMMA bone cement, ES-PMMA bone cement reduced local thrombosis, possibly by regulating vascular endothelial CD40 protein expression.

Conclusion
In summary, using a simple and reproducible animal model, we proved that PMMA produces local thrombosis and that compared with PMMA, ES-PMMA, a novel material, can reduce local thrombosis A, possibly by regulating low protein expression protein on endothelial cells in vascular tissue.

Abbreviations
PMMA: Polymethylmethacrylate; ES: Enoxaparin sodium; SEM: Scanning electron microscopy.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12891-022-05469-5.

Acknowledgements
Not applicable.

Authors’ contributions
Study conception and design: Sang, Qi. Acquisition of data: Sang, Hao, Ding. Analysis and interpretation of data: Sang, Sun. Drafting of manuscript: Sang, Shen. Critical revision: Fu, Qi. All authors read and approved the final manuscript.

Funding
This study was supported by the Government Funded the Training of Outstanding Talents in Clinical Medicine and Basic Research Project and Xinjiang Project.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All experiments were performed in strict accordance with the guidelines for care and use of laboratory animals and were approved by the medical ethics committee of the Third Medical College of Hebei Medical University; ethics acceptance No. z2021–007-2. The study was carried out in compliance with the ARRIVE guidelines.

Competing interests
This material has not been published and is not under consideration elsewhere. The authors declare that they have no competing interests. All authors have read and contributed to the submitted manuscript, and there is no conflict of interest among the authors.

Author details
1 Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China. 2 Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita, Japan. 3 Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

Received: 8 March 2022 Accepted: 23 May 2022
Published online: 30 May 2022

References
1. Kaufmann KB, Baar W, Rexer J, Loeffler T, Heinrich S, Konstantinidis L, et al. Evaluation of hemodynamic goal-directed therapy to reduce the incidence of bone cement implantation syndrome in patients undergoing cemented hip arthroplasty - a randomized parallel-arm trial. BMC Anesthesiol. 2018;18(1):63. https://doi.org/10.1186/s12871-018-0526-4.
2. Rassir R, Schuiling M, Siersevelt IN, van der Hoeven CWP, Nolte PA. What are the frequency, related mortality, and factors associated with bone cement implantation syndrome in arthroplasty surgery? Clin Orthop Relat R. 2021;479(4):755–63. https://doi.org/10.1186/s12871-018-0526-4.
3. Hu C, Liu C, Wang Y, Ding T, Sun K, Tian S. The timing of symptomatic pulmonary embolism in patients with nonwarfarin anticoagulants following elective primary Total joint arthroplasty. J Arthroplast. 2020;35(6):1703–7. https://doi.org/10.1186/s12871-018-0526-4.
4. Cenni E, Granchi D, Vancini M, Pizzoferrato A. Platelet release of transforming growth factor-beta and beta-thromboglobulin after in vitro contact with acrylic bone cements. Biomaterials. 2002;23(6):1479–84. https://doi.org/10.1016/S0142-9693(02)00099-7.
5. Zindel S, Stock S, Müller D, Stollwerck B. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res. 2012;12(1):192. https://doi.org/10.1186/1472-6963-12-192.
6. Sun H, Ma X, Li Z, Liu J, Wang W, Qi X. Release characteristics of enoxaparin sodium-loaded polymethylmethacrylate bone cement. J Orthop Surg Res. 2021;16:108. https://doi.org/10.1186/s12871-018-0526-4.
7. Herzog E, Kasperet M, Kriege W, Doer R, van Ryn J, Dickneite G, et al. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thromb Res. 2014;134(3):729–36. https://doi.org/10.1016/j.thromres.2018-05-026.
8. Olsen F, Hård Af Segerstad M, Nellgård B, Hol'tz E, Ricksten SE. The role of bone cement for the development of intraoperative hypotension and hypoxia and its impact on mortality in hemiarthroplasty for femoral neck fractures. Acta Orthop. 2020;91(3):293–8. https://doi.org/10.1186/s12871-018-0526-4.
9. Kang HR, Kim TH, Chung CK, Lee CH. The impact of incidental pulmonary cement embolism on mortality risk. J Thromb Thrombolysis. 2020;49:68–74. https://doi.org/10.1186/s12871-018-0526-4.
10. Jing BB, Li YX, Zhang H, Ren ST, Wang M, Li YP, et al. Antithrombotic activity of Z4A5, a new platelet glycoprotein Ib/IIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model. Thromb Res. 2011;128(5):463–9. https://doi.org/10.1016/j.thromres.2011.06.015.

11. Kerpel-Noreuil KM, Lozier J, Oden N, Taneja A, Burton-Akrigh J, Sapp JC, et al. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome. Am J Med Genet C. 2019;181(4):571–81. https://doi.org/10.1002/ajmg.c.38264.

12. Toh CH, Alhamdi Y, Abrams ST. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation. Ann Lab Med. 2016;36(6):505–12. https://doi.org/10.3343/aml.2016.36.6.505.

13. Liu Liu Y, Hu M, Luo D, Yue M, Wang S, Chen X, et al. Class III PI3K positively regulates platelet activation and thrombosis via PI (3) P-directed function of NADPH oxidase. Arterioscl Throm Vasc Biol. 2017;37(11):2075–86. https://doi.org/10.1161/ATVBAHA.117.311444.

14. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15(1):130. https://doi.org/10.1186/s12871-015-0264-9.

15. Zhang Y, Liu J, Ji W, Tian X, Jiang P, Cheng Z, et al. A reactive Centre loop of antithrombin in the presence of heparin. J Biochem. 2012;152(5):463–70. https://doi.org/10.1016/j.jbchem.2012.09.001.

16. Hickey BA, Cleves A, Alikhan R, Pugh N, Nokes L, Perera A. Can we use biomarkers of coagulation to predict which patients with foot and ankle injury will develop deep vein thrombosis? Foot Ankle Surg. 2019;25(1):59–62. https://doi.org/10.1016/j.fas.2018.08.001.

17. Wang Z, Zhu J. Structural determinants of the integrin transmembrane domain required for bidirectional signal transmission across the cell membrane. J Biol Chem. 2021;297(5):101318. https://doi.org/10.1002/jbc.2021041318.

18. Hubert L, Darbousset R, Panicot-Dubois L, Robert S, Sabatier F, Fallague K, et al. Neutrophils recruit and activate human endothelial colony-forming cells at the site of vessel injury via P-selectin glycoprotein ligand-1 and L-selectin. J Thromb Haemost. 2014;12(7):1170–81. https://doi.org/10.1111/jth.12526.

19. Feng X, Sun B, Liu S, Li D, Yang X, Zhang Y. Identification of thrombomodulin as a dynamic monitoring biomarker for deep venous thrombosis evolution. Exp Ther Med. 2021;21(2):142. https://doi.org/10.3892/etm.2020.8481.

20. Wang Z, Zhu J. Structural determinants of the integrin transmembrane domain required for bidirectional signal transmission across the cell membrane. J Biol Chem. 2021;297(5):101318. https://doi.org/10.1002/jbc.2021041318.

21. Senchenkova EY, Russell J, Vital SA, Yildirim A, Orr AW, Granger DN, Gavins FF. A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation. Faseb J. 2018;32(6):3448–3456. https://doi.org/10.1002/ff.7643.

22. Jiang RH, Xu QX, Wu CJ, Lu SS, Zu QQ, Zhao LB, et al. The CD40/CD40L system regulates rat cerebral microvasculature after focal ischemia/reperfusion via the mTOR/S6K signaling pathway. Neurol Res. 2018;40(9):717–23. https://doi.org/10.1179/174313281603X16692.

23. Popa M, Tahir S, Eldr, Kim SH, Leuschner F, Kessler T, et al. Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction. P Natl Acad Sci USA. 2011;115(24):E5545–6. https://doi.org/10.1073/pnas.1103460115.

24. Tang T, Cheng X, Lu X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Therapeut. 2021;1219107709. https://doi.org/10.1016/j.pharmthera.2021.107709.

25. Nakatomi Y, Tsujii M, Gokudan S, Hanada-Dateki T, Nakashima T, Miyazaki H, et al. Stable complex formation between serine protease inhibitor and zymogen: coagulation factor X cleaves the Arg393-Ser394 bond in a reactive Centre loop of antithrombin in the presence of heparin. J Biochem. 2012;152(5):465–70. https://doi.org/10.1093/jb/mvs073.

26. Papadaki S, Tsileps AD. Nonhemostatic Activities of Factor Xa. Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants? Angiology. 2019;70(10):896–907. https://doi.org/10.1118/12871-018-0526-4.

27. Weiss SAJ, Rehm SRT, Perera NC, Binossek ML, Schilling O, Jenne DE. Origin and expansion of the serine protease repertoire in the Myelomonocytic lineage. Int J Mol Sci. 2021;22(4):1658. https://doi.org/10.1186/s12871-018-0526-4.

28. Javacas C, Stordeur P, Azarkan M, Mascart F, Baeyens-Volant D. Isolation of a thiol-dependent serine protease in peanut and investigation of its role in the complement and the allergic reaction. Mol Immunol. 2016;75:133–43. https://doi.org/10.1016/j.molimm.2016.07.019.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions